The Impact of Polymorphisms ABCB1 on the Eff ectiveness and Safety of Fluvoxamine in Patients with Depressive Disorder with Comorbid Alcoholism

Fluvoxamine is used to treat patients with depressive disorders. A large proportion of patients in this
group do not adequately respond to fl uvoxamine therapy, while many people develop undesirable
drug reactions (NLR) of type A. According to the results of previous studies, it was showed that P-gp
is highly involved in biotransformation. Its activity highly depends on the polymorphism of the gene
encoding it. The aim of our research was to study the eff ect of fl uvoxamine gene polymorphism on
the eff ectiveness and safety of fl uvoxamine therapy in patients with depressive disorders, comorbid
with alcohol dependence.
The study included 119 male patients with depressive disorders, comorbid with alcohol addiction
(aged 38.5±15.8 years). Fluvoxamine at the dose of 123.9±51.6 mg / day was used as therapy.
Evaluation of the eff ectiveness profi le was carried out using psychometric scales. The safety profi le
was evaluated using the UKU Side-Eff ect Rating Scale. Genotyping was carried out with polymerase
chain reaction in real time.
According to the results of the study, statistically signifi cant results were not obtained in terms of
evaluating the eff ectiveness and safety. HAMD scores at the end of the course of therapy were the
following: (CC) 2.0 [1.0; 3.2], (CT) 2.0 [1.0; 4.0] and (TT) 2.0 [1.0; 3.0], p=0.686; on the UKU scale: (CC)
6.0 [5.0; 6.0], (CT) 6.0 [6.0; 7.0] and (TT) 6.5 [6.0; 7.0], p=0.008.
In the study of a group of 119 patients with depressive disorders, comorbid with alcohol addiction,
the absence of the eff ect of 3435C>T polymorphism of the ABCB1 gene (rs1045642) on the clinical
eff ectiveness and safety of fl uvoxamine was demonstrated.